Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
340 participants
OBSERVATIONAL
2020-09-30
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of the Virtual Unified Huntington's Disease Rating Scale
NCT05748288
A Pilot Study of Nutritional Status in Patients With Huntington's Disease
NCT05668520
Handgrip and Respiratory Dysfunction in HD Patients.
NCT06585332
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Longitudinal Endpoint Assessment of Disease Burden in HD
NCT06475898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Individual of either gender
2. Fluent in English
3. Must be willing and able to provide informed consent or have a legal representative willing and able to provide assent
Manifest HDGEC Participants
1. Must be an active participant in the Enroll-HD study. An active participant is defined as a participant who has successfully enrolled in the Enroll-HD study and completed the Enroll-HD study baseline visit.
2. Age≥20 years
3. CAG repeat length≥36
4. DCL=4
5. Inclusion score of 16 at the time of the participant's most recent Enroll-HD study visit (for inclusion score calculation, see Appendix A - Inclusion Score Calculation) Companion Participants
1\. Age≥18 years 2. A person who, in his/her opinion, has sufficient interface and knowledge of the Manifest HDGEC Participant's capabilities and daily activities 3. Acceptable to the Manifest HDGEC Participant and the Site Investigator or the Site Investigator's designees
Exclusion Criteria
1. Individuals with choreic movement disorders in the context of a laboratory verified non-expansion mutation for the Huntingtin gene
2. Manifest HDGEC Participants with Juvenile-onset HD (rater estimate of age of onset \<20 years old)
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHDI Foundation, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Birmingham, Alabama, United States
Regents of the University of California, San Diego
La Jolla, California, United States
Regents of the University of California, Los Angeles
Los Angeles, California, United States
Rocky Mountain Movement Disorders Center, P.C
Englewood, Colorado, United States
Rush Universiity Medical Center
Chicago, Illinois, United States
Hereditary Neurological Disease Centre, Inc.
Wichita, Kansas, United States
Washington University
St Louis, Missouri, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
University of Washington
Seattle, Washington, United States
The Chancellor, Masters and Scholars of the University of Cambridge
Cambridge, Cambridgeshire, United Kingdom
Cardiff University
Wales, Cardiff, United Kingdom
Royal Devon and Exeter NHS Foundation Trust
Exeter, Devon, United Kingdom
Poole Hospital NHS
Poole, Dorset, United Kingdom
Leicestershire Partnership NHS Trust
Leicester, Leicestershire, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, Leicester, United Kingdom
Northumberland, Tyne &Wear NHS Foundation Trust of St. Nicholas Hospital
Newcastle upon Tyne, Tyne & Wear, United Kingdom
Birmingham and Solihull Mental Health NHS Foundation
Birmingham, West Midlands, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, Yorkshire, United Kingdom
University Hospitals Plymouth NHS Trust
Plymouth, , United Kingdom
Sheffield Children's NHS Foundation Trust
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-000619
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.